Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Esperion Theraptc (NQ: ESPR ) 2.390 -0.060 (-2.45%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Esperion Theraptc < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > "CLEAR" Progress At Esperion September 16, 2023 Esperion Therapeutics, Inc. continues to showcase their positive CLEAR data, with two oral presentations at the European Society of Cardiology 2023 Congress. Here is a closer look at some highlights. Via Talk Markets American College of Cardiology Program to Increase Cholesterol Screenings September 12, 2023 From Esperion Therapeutics, Inc.; The American College of Cardiology Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session August 30, 2023 Via Benzinga Why Is Esperion Therapeutics Stock Trading Higher Today? August 28, 2023 Esperion Therapeutics Inc (NASDAQ: ESPR) announced the presentation of results from two CLEAR Outcomes Study Late-Breakers at the European Via Benzinga Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference August 28, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire 5 Analysts Have This to Say About Esperion Therapeutics August 02, 2023 Via Benzinga Analyst Expectations for Esperion Therapeutics's Future June 26, 2023 Via Benzinga Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023 August 26, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023 August 11, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 08, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Reports Second Quarter 2023 Financial Results August 01, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Analyst Ratings for Esperion Therapeutics June 01, 2023 Via Benzinga Esperion to Participate in BTIG Virtual Biotechnology Conference 2023 July 24, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion to Report Second Quarter 2023 Financial Results on August 1 July 17, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 July 07, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet June 28, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions June 24, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023 June 15, 2023 Cardiovascular risk reduction with bempedoic acid shown via the Cholesterol Treatment Trialists’ (CTT) Major Vascular Event endpoint is comparable to the normalized risk reduction with statins observed... From Esperion Therapeutics, Inc. Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023 June 15, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 15, 2023 Via Benzinga Verastem To Rally Around 287%? Here Are 10 Other Analyst Forecasts For Thursday June 15, 2023 Piper Sandler boosted the price target for Accenture plc (NYSE: ACN) from $250 to $316. Piper Sandler analyst Arvind Ramnani upgraded the stock from Underweight to Neutral. Accenture shares rose 1.1%... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday June 15, 2023 It's time to start breaking down the biggest pre-market stock movers for Thursday as we get ready for another busy day of trading! Via InvestorPlace Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023 June 08, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023 June 05, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet June 01, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders May 25, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion to Participate in Jefferies Healthcare Conference May 24, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 12, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying May 11, 2023 The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... Via Benzinga Esperion Reports First Quarter 2023 Financial Results May 09, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.